

# Pharmacological prophylactic protocol for prevention of postoperative nausea and vomiting after Endoscopic Sleeve Gastroplasty



SAPIENZA  
UNIVERSITÀ DI ROMA

**Loredana Gualtieri**



Department of Surgical Science  
"Umberto I" Hospital  
«Sapienza» University – Rome, Italy



**No potential conflict of interest to report**

# ENDOSCOPIC SLEEVE GASTROPLASTY

- ❖ REVERSIBLE
- ❖ MINIMALLY INVASIVE
- ❖ ENDOLUMINAL
- ❖ ORGAN SPARING






# BACKGROUND



THE LANCET

Log in 

ARTICLES | VOLUME 400, ISSUE 10350, P441-451, AUGUST 06, 2022

 Download Full Issue

Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial

Prof Barham K Abu Dayyeh, MD   • Fateh Bazerbachi, MD • Eric J Vargas, MD • Reem Z Sharaiha, MD •

Prof Christopher C Thompson, MD • Bradley C Thamer, MD • et al. [Show all authors](#)

Published: July 28, 2022 • DOI: [https://doi.org/10.1016/S0140-6736\(22\)01280-6](https://doi.org/10.1016/S0140-6736(22)01280-6) •  Check for updates

«*ESG is a safe intervention that resulted in significant weight loss, maintained at 104 weeks, with important improvements in metabolic comorbidities. ESG should be considered as a synergistic weight loss intervention for patients with class 1 or class 2 obesity.*»


Obesity Surgery (2021) 31:70–78  
<https://doi.org/10.1007/s11695-020-04915-4>



ORIGINAL CONTRIBUTIONS



## Brazilian Consensus on Endoscopic Sleeve Gastroplasty

Manoel Galvão Neto<sup>1,2</sup> • Lyz Bezerra Silva<sup>3</sup> • Luiz Gustavo de Quadros<sup>2,4</sup> • Eduardo Grecco<sup>1,2</sup> • Admar Concon Filho<sup>2,5</sup> • Artagnan Menezes Barbosa de Amorim<sup>6</sup> • Marcelo Falcao de Santana<sup>7</sup> • Newton Teixeira dos Santos<sup>8</sup> • Joao Henrique Felicio de Lima<sup>9</sup> • Thiago Ferreira de Souza<sup>1,2</sup> • Helmut Wagner Poti de Moraes<sup>10</sup> • Felipe Matz Vieira<sup>11</sup> • Rena Moon<sup>12</sup> • André F. Teixeira<sup>12</sup>  • for the Brazilian Endoscopic Sleeve Gastroplasty Collaborative

Mean percentage total body weight loss (TBWL) of 18.2% in 1 year

# BACKGROUND

## Five-Year Outcomes of Endoscopic Sleeve Gastroplasty for the Treatment of Obesity

Reem Z. Sharaiha<sup>\*</sup>, Kaveh Hajifathalian<sup>\*</sup>, Rekha Kumar<sup>‡</sup>, Katherine Saunders<sup>‡</sup>, Amit Mehta<sup>\*</sup>, Bryan Ang<sup>§</sup>, Daniel Skaf<sup>§</sup>, Shawn Shah<sup>\*</sup>, Andrea Herr<sup>\*</sup>, Leon Igel<sup>‡</sup>, Qais Dawod<sup>\*</sup>, Enad Dawod<sup>§</sup>, Kartik Sampath<sup>\*</sup>, David Carr-Locke<sup>\*</sup>, Robert Brown<sup>\*</sup>, David Cohen<sup>\*</sup>, Andrew J. Dannenberg<sup>||</sup>, Srihari Mahadev<sup>\*</sup>, Alpana Shukla<sup>‡</sup>, Louis J. Aronne<sup>‡</sup>

- ❖ Mild adverse events rate was: **32%**
- ❖ «patients experienced nausea and vomiting: **19%**»

❖ « **31.2%** of patients reported postprocedure nausea »

A single-operator learning curve analysis for the endoscopic sleeve gastroplasty

Monica Saumoy, MD, MS • Yecheskel Schneider, MD, MS • Xi Kathy Zhou, PhD • ... Michel Kahaleh, MD • Louis Aronne, MD • Reem Z. Sharaiha, MD, MSc • Show all authors

Published: August 24, 2017 • DOI: <https://doi.org/10.1016/j.gie.2017.08.014> • Check for updates

## Efficacy and Safety of Endoscopic Sleeve Gastroplasty: A Systematic Review and Meta-Analysis

Abdellah Hedjoudje<sup>\*</sup>, Barham Abu Dayyeh<sup>‡</sup>, Lawrence J. Cheskin<sup>§</sup>, Atif Adam<sup>||</sup>, Manoel Galvão Neto<sup>||, #</sup>, Dilhana Badurdeen<sup>\*</sup>, Javier Graus Morales<sup>\*\*</sup>, Adrian Sartoretto<sup>##</sup>, Gontrand Lopez Nava<sup>§§</sup>, Eric Vargas<sup>|||</sup>, Sui Zhixian<sup>##, ¶¶</sup>, Lea Fayad<sup>\*</sup>, Jad Farha<sup>\*</sup>, Mouen A. Khashab<sup>\*</sup>, Anthony N. Kalloo<sup>\*</sup>, Aayed R. Alqahtani<sup>##, \*\*\*</sup>, Christopher Thompson<sup>+++</sup> and Vivek Kumbhari<sup>\*</sup>

- ❖ «The pooled 95 post-ESG rate of severe adverse events was: **2.2%** (95% CI, 1.6%–3.1%];»
- ❖ «nausea requiring hospitalization: n=18, **1.08%**;»

## PRIMARY OUTCOME



- To evaluate the **EFFICACY OF PROPHYLACTIC ANTI-EMETIC MEDICATION PROTOCOL**
- **OTHER ADVERSE EVENTS**

## SECONDARY OUTCOME

**WEIGHT LOSS RESULTS**





# AIM AND METHOD

10 patients, aged 24 – 62, with a **mean BMI of 35.8 kg/m<sup>2</sup>**






were enrolled and submitted to



**ENDOSCOPIC SLEEVE GASTROPLASTY**

**Follow-up:  
6 months**

**“U” PATTERN**



# ANTIEMETIC PROTOCOL

➤ **PRE-operatively**  
At least 1 hour  
before procedure

i.v.  
**150mg Fosaprepitant**  
(Ivemend)

neurokinin 1  
(NK1) receptor  
antagonist

➤ **INTRA-operateively**

i.v. **0.15mg/kg ondasetron**  
i.v. **8mg dexamethasone**

serotonin 5-HT3  
receptor  
antagonist

➤ **POST-operatively**  
every 12 hours for the  
next 24 hours

i.v.  
**8mg ondasetron**



## ADVERSE EVENTS



❖ **No patients experienced nausea or vomiting in the postoperative period.**

❖ **2/10 patients experienced mild epigastric pain treated with medical therapy.**

# RESULTS

## WEIGHT LOSS OUTCOMES

### BMI REDUCTION



❖ MEAN  
%TBWL:  
14.3

❖ MEAN  
%EWL: 55.7

# CONCLUSION

**In our preliminary experience, our anti-emetic protocol (Fosaprepitant + dexamethasone + ondasetron) has proven effective in 100% of cases.**

**Endoscopic Sleeve Gastroplasty has been shown to be effective in terms of weight loss outcomes in short term.**





**THANK YOU**